02268.HK
WuXi XDC Cayman Inc
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 77.00
+0.65%Year over year
Reported trailing growth
- Revenue
- +35.5%
- EBITDA
- +48.1%
- EBIT
- +47.5%
- EPS
- +22.0%
- Free cash flow
- +730.8%
- Operating cash flow
- -21.1%
Forward estimates
Based on analyst estimates
- Revenue
- +114.5%
- EBITDA
- +173.8%
- EPS
- +150.0%
Three-year CAGR
- Revenue
- +81.7%
- EBITDA
- +126.6%
- EBIT
- +134.4%
- Net income
- +111.8%
- EPS
- +110.9%
- Free cash flow
- +132.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026